|
|
|
| Inhibitive Effects of 17act-D-homo Ethynylestradiol-3-acetate in Tumor-bearing Mice |
| HAN Ying, SONG Na-ling, WANG Yue-ying, SUN Yuan-ming, WU Hong-ying, LI De-guan |
| Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192 China |
|
|
|
|
Abstract Objective To observe the inhibitory effect of 17act-D-homo ethynylestradiol-3-acetate combined 137Cs radiation in leukemia L1210 cells. Methods The animal model of leukemia (L1210) was prepared by tumor cell inoculation. All animal divided into six groups, control group, group treated only with radiation, 17act-D-homo ethynylestradiol-3-acetate high-level group, 17act-D-homo ethynylestradiol-3-acetate mid-level group, 17act-D-homo ethynylestradiol-3-acetate low-level group and group combined E838 and radiation. Mice with leukemia (L1210) followed intraperitoneal injection of 17act-D-homo ethynylestradiol-3-acetate once a day for 7 days. Tumor inhibition rate, the number of bone marrow nucleated cells, thymus index and spleen index were detected at the fifth day after the last administration and compare the difference in different groups. Results Tumor in every groups treated with 17act-D-homo ethynylestradiol-3-acetate significant smaller than the control. 17act-D-homo ethynylestradiol-3-acetate combined radation has great inhibition effect in tumor-bearing mice (L1210). Conclusion 17act-D-homo ethynylestradiol-3-acetate has significant inhibition effect in leukemia (L1210) and could protect the immune organs in mice. 17act-D-homo ethynylestradiol-3-acetate combined radiation could enhance the anti-tumor therapy.
|
|
Received: 24 February 2012
|
|
|
|
|
|
|
|
|
